These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Development of acetylated HDD kit for preparation of 188Re-HDD/lipiodol. Lee YS, Jeong JM, Kim YJ, Chang YS, Lee HJ, Son M, Lee JW, Yoon HS, Kang WJ, Lee DS, Chung JK, Lee MC, Suh YG. Appl Radiat Isot; 2007 Jan; 65(1):64-9. PubMed ID: 17010628 [Abstract] [Full Text] [Related]
5. Advantage of 188Re-radiopharmaceuticals in hepatocellular cancer and liver metastases. Liepe K, Kotzerke J, Lambert B. J Nucl Med; 2005 Aug; 46(8):1407-8; author reply 1407-8. PubMed ID: 16085601 [No Abstract] [Full Text] [Related]
8. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. Lambert B, Bacher K, Defreyne L, Gemmel F, Van Vlierberghe H, Jeong JM, Dierckx RA, Van de Wiele C, Thierens H, De Vos F. J Nucl Med; 2005 Jan; 46(1):60-6. PubMed ID: 15632035 [Abstract] [Full Text] [Related]
11. A kit formulation for the preparation of 188Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma. Boschi A, Uccelli L, Duatti A, Colamussi P, Cittanti C, Filice A, Rose AH, Martindale AA, Claringbold PG, Kearney D, Galeotti R, Turner JH, Giganti M. Nucl Med Commun; 2004 Jul; 25(7):691-9. PubMed ID: 15208496 [Abstract] [Full Text] [Related]
16. Automated preparation of Re-188 lipiodol for the treatment of hepatocellular carcinoma. Uccelli L, Pasquali M, Boschi A, Giganti M, Duatti A. Nucl Med Biol; 2011 Feb; 38(2):207-13. PubMed ID: 21315276 [Abstract] [Full Text] [Related]